مراجعة
Etesevimab and Bamlanivimab
| العنوان: | Etesevimab and Bamlanivimab |
|---|---|
| المصدر: | 2006. |
| المصدر: | In: Drugs and Lactation Database (LactMed) |
| نوع المنشور: | Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: National Library of Medicine (US) Cited Medium: Internet |
| أسماء مطبوعة: | Bethesda (MD) : National Library of Medicine (US) |
| مستخلص: | The distribution of etesevimab and bamlanivimab was stopped in June of 2021 because of a lack of efficacy against COVID-19 variants. Etesevimab and bamlanivimab are monoclonal antibodies directed against the SARS-CoV-2 virus that causes COVID-19. No information is available on their clinical use during breastfeeding. Because etesevimab and bamlanivimab are large protein molecules with molecular weights of 146,000 Da, the amount in milk is likely to be very low. They are also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Until more data become available, etesevimab and bamlanivimab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. Etesevimab and bamlanivimab are human immunoglobulin G1 (IgG1) antibodies. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1,2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity. |
| فهرسة مساهمة: | Keywords: Etesevimab; LYCoV016; anti-Sars-cov-2 antibody JS016; CB6; LY-3832479; LY-COV016; LY3832479; NP005; UNII-N7Q9NLF11I; WHO 11873; Bamlanivimab; LY-3819253; LY-COV555; LY3819253; UNII-45I6OFJ8QH |
| رمز التحديث: | 20240629 |
| PMID: | 33630482 |
| Book AN: | NBK567880 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!